544 results about "Reducing bodies" patented technology

A physical and mental health status monitor, analyze and follow up clothing system. Whose purpose is to monitor the user's body fat distribution, muscular activity and position changes to diagnose health status. Regularly giving suggestions to the user to achieve proper exercise and posture to reduce body fat and prevent muscular atrophy. While correcting the user's life style to promote better health, this system also works to reduce mental and emotional stress. Providing better healthcare and reducing the chance of disease. This system includes sensors, a close range monitoring system and long range monitoring stations, through the sensors it collects data for the monitoring system and monitoring stations to observe, analyze, diagnose and follow up on the user's physical and mental state. This system also allows the user and the long range monitoring stations to communicate with each other through the close range monitoring system.

A reinforced catheter having a multi-layered structure suitable for medical uses comprising an inner liner, a braided reinforced layer adjacent to the inner liner, a first resin adjacent to the braided layer, and a harder second resin overlaying the first resin; wherein, the first resin and second resin taper inversely to one another along the length of the catheter, thereby forming a co-tapered soft tip that reduces body trauma.

By introducing a atomic species, such as carbon, fluorine and the like, into the drain and source regions, as well as in the body region, the junction leakage of SOI transistors may be significantly increased, thereby providing an enhanced leakage path for accumulated minority charge carriers. Consequently, fluctuations of the body potential may be significantly reduced, thereby improving the overall performance of advanced SOI devices. In particular embodiments, the mechanism may be selectively applied to threshold voltage sensitive device areas, such as static RAM areas.

This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.

The invention relates generally to methods and apparatus for inducing hypothermia in an animal. Known methods for inducing hypothermia all involve cooling the outside or inside of an animal, sometimes in conjuction with drugs that disable the animal's homeostatic responses. The present invention is directed to a method and apparatus for applying heat to the hypothalamus of a warm-blooded animal in order to utilize the physiological mechanisms that regulate body temperature to effect a compensatory cooling response, thereby lowering body temperature. It is new and unsuggested in the art to apply heat in an effort to reduce body temperature. The invention effects the desired lowering of body temperature by the method od raising the temperature of the hypothalamus, a brain structure situated in humans just above the pituitary gland responsible for temperature regulation, by warming a nasal passage, or a sinus, such as the sphenoid sinus that is nearest to the hypothalamus, or by direct warming of the hypothalamus, or a combination of these.

The Ice Belt To Reduce Body Temperature is a belt made of a turned out strip of flexible material of amble width and length to gird the waist from the midriff down, contains pocket-like receptacles on its innermost body-contacting side for the placement of flexible ice bags, and is secured around the waist by a connecting means. The Ice Belt to Reduce Body Temperature is a new concept of belts intended for sports, exercise and safety because the Ice Belt To Reduce Body Temperature provides the wearer with the comfort of a lower body temperature when exposed to high climatic conditions. In fact, most belts pertaining to the prior art are designed to promote sweating—a symptom of high body temperature—rather than reduce sweating. Therefore, the Ice Belt helps to lessen the risk of the user acquiring heat exhaustion when exposed to high climatic conditions.

This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and / or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxyvitamin D2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R1, R2, and R3 have the values described herein.

Buck converters having a resonant inductor Lr, resonant capacitor Cr, and synchronous switch Q3 that together provide reduced switching loss and soft switching. In operation, the resonant inductor Lr is charged during a time period A. Then, Lr is freewheeling and provides current to an output inductor Lo. Then, Q3 is turned OFF, and energy from the resonant inductor Lr charges the resonant capacitor Cr. Finally, energy from the resonant capacitor Cr is provided to the output inductor and load. The output power can be adjusted by phase control of the operation of switch Q3. In alternative embodiments, the circuit has a pair of coupled inductors L1 L2 or an isolation transformer 40. The coupled inductors have a polarity selected so that the output voltage is reduced, thereby allowing top switch Q1 to have a greater duty cycle. These circuits feature no body diode loss in the switch Q3.

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

Improved methods and devices are provided for detecting and / or predicting the onset of an undesirable physiological event or neural state, such as an epileptic seizure, to facilitate rapid intervention with a treatment therapy such as neurostimulation or drug therapy. The methods and devices involve monitoring the patient's body temperature, preferably by an implanted temperature sensor, to detect a change in a body temperature parameter over a first time period. The temperature parameter change may comprise an increase or decrease in the patient's body temperature over a first time period, time rate of change of body temperature over a first time period, a moving average temperature over a first time period, an increase or decrease in body temperature exceeding a target temperature over a first time period, an elevated or reduced body temperature over first time period, or a temperature stability parameter over a first time period. The sampling period at which body temperature measurements are made may be changed manually or depending upon a sensed body parameter, including temperature. When a parameter change is detected that exceeds a threshold, neurostimulation therapy is delivered to a neural structure of the patient.

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and / or implantation of such compositions.

Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I):or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, and R4 are as defined herein.

The invention provides methods and pharmaceutical compositions for administering a PPARα agonist (e.g., OEA-like agonist, OEA-like compound), an OEA-like appetite reducing compound, or a FAAH inhibitor and a CB1 cannabinoid receptor antagonist to a subject in order to reduce the consumption or ingestion of food, ethanol or other appetizing substances as well as in treating appetency disorders related to the excess consumption of food, ethanol, and other appetizing substances. The combination therapy can also be useful for reducing body fat or body weight and modulating lipid metabolism.

A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.

A method is disclosed utilizing an optically pure eutomer of salbutamol for reducing body fat and / or body weight in mammals and birds. A food composition including the eutomer is also disclosed.

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and / or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect the composition of the present invention further comprises carboxy alkyl ester. The present invention also relates to a method of promoting internal health and external appearance in a subject in need, said method comprising administering to the subject a composition that promotes DNA repair, reduces body fat levels and increases lean body mass and that decreases wrinkle appearance and / or improvement in skin surface.

The present application relates to an insulation pack in a wearable article, such as a footwear article. In one example embodiment, the insulation pack includes a perforated air retention and communication layer, an insulating compressible layer, and a reflective layer. In a compressed state, when the wearable article is worn by a wearer, the perforated air retention and communication layer and the insulating compressible layer maintain a lofted air space which is in air communication with an inner body space of the wearable article and acts as an insulating layer. Further, the reflective layer reflects radiated body heat. Thus, the insulation pack may provide a heat retention and insulation system for the wearable article by reducing body heat lost via radiation and conduction.

For fabricating a field effect transistor, an extra-doped channel region is formed below a surface of a semiconductor substrate. An opening is formed in the semiconductor substrate into the extra-doped channel region. A gate insulator is formed at walls of the opening such that the extra-doped channel region abuts the gate insulator at a bottom portion of the opening. The opening is filled with a gate electrode. Such an extra-doped channel region prevents undesired body effect in the field effect transistor.

Active cooling of a person, such as to induce mild / moderate hypothermia, is accomplished by transferring heat from the persons body. Heat transfer and patient comfort are aided by administration of an anti-shivering drug and an anti-emetic drug.

The invention relates, in part, to of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions that are associated with impaired glucose tolerance such as diabetes. The invention also relates to compositions of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions such as metabolic syndrome, dyslipidemias, inflammation, cardiovascular disorders such as hypertension and atherosclerosis, and to reduce body weight or prevent weight gain. The compounds of the invention are also useful in lowering levels of triglycerides, free fatty acids, C-reactive protein (CRP), HbA1C, total glycosylated hemoglobin (TGHb), in increasing insulin sensitivity index and in stimulating insulin release.

The invention discloses a system and a method using VGF and VB growing technology to carry out crystal growth to reduce body inlaid crystal. In a demonstration embodiment, an ampoule bottle containing a raw material is inserted into a furnace with a heating resource, and a vertical gradient solidifying technology is used for crystal growth, wherein the crystallizing temperature gradient can move corresponding to the crystal and / or the furnace to melt the raw material and convert the raw material into monocrystal compound; and a vertical Bridgman technology is used for crystal growth on a crucible, wherein the ampoule bottle / heating source can relatively move to continuously melt the raw material and convert the raw material into monocrystal compound.

In a FinFET integrated circuit, the fins are formed with a reduced body thickness in the body area and then thickened in the S / D area outside the body to improve conductivity. The thickening is performed with epitaxial deposition while the lower portion of the gates are covered by a gate cover layer to prevent thickening of the gates at the fin level, which may short the gate to the S / D.

The present invention relates to naturally occurring compositions comprising vitamin D3 or related analog and methods for treating obesity and / or osteoporosis and reducing body fat or enhancing a bone graft in patients in need thereof.

A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.

Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.